De novo mutational signature discovery in tumor genomes using SparseSignatures

22Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Cancer is the result of mutagenic processes that can be inferred from tumor genomes by analyzing rate spectra of point mutations, or “mutational signatures”. Here we present SparseSignatures, a novel framework to extract signatures from somatic point mutation data. Our approach incorporates a user-specified background signature, employs regularization to reduce noise in non-background signatures, uses cross-validation to identify the number of signatures, and is scalable to large datasets. We show that SparseSignatures outperforms current state-of-the-art methods on simulated data using a variety of standard metrics. We then apply SparseSignatures to whole genome sequences of pancreatic and breast tumors, discovering well-differentiated signatures that are linked to known mutagenic mechanisms and are strongly associated with patient clinical features.

Cite

CITATION STYLE

APA

Lal, A., Liu, K., Tibshirani, R., Sidow, A., & Ramazzotti, D. (2021). De novo mutational signature discovery in tumor genomes using SparseSignatures. PLoS Computational Biology, 17(6). https://doi.org/10.1371/journal.pcbi.1009119

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free